CRISPR, Are We Ready to Rewrite the Human Genome?
Rachel Sachs (Academic Fellow) was a speaker at the ECUSA Boston event "CRISPR, Are We Ready to Rewrite the Human Genome?" on March 24, 2016.
The gene editing tool CRISPR has revolutionized biological science and has a powerful therapeutic potential ranging from inherited diseases to Alzheimer’s, cancer or bacterial infections. The biggest advantage of CRISPR technology is its simplicity to implement changes in DNA that remain stable, resulting in a truly edited genome. However, the implications of CRISPR are well beyond experimental science: are we ready to rewrite the human genome?
Read about the event
Watch video of the event
Tags
biotechnology genetics health law policy rachel sachs regulation